Last checked at 31 Mar 2021 15:00
Shield Therapeutics plc
("Shield" or the "Group")
Block Listing 6 Monthly Return
Date: 31 March 2021
Name of applicant: | SHIELD THERAPEUTICS PLC
| |||
Name of scheme: | Shield Therapeutics Retention Share Plan | |||
Period of return: | From: | 01 October 2020 | To: | 31 March 2021 |
Balance of unallotted securities under scheme(s) from previous return: | 54,219 | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | NIL | |||
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | -14,425 | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 39,794 | |||
Name of applicant: | SHIELD THERAPEUTICS PLC
| |||
Name of scheme: | Shield Therapeutics plc 2016 Company Share Option Plan | |||
Period of return: | From: | 01 October 2020 | To: | 31 March 2021 |
Balance of unallotted securities under scheme(s) from previous return: | 388,079 | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | NIL | |||
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | NIL | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 388,079 | |||
Name of applicant: | SHIELD THERAPEUTICS PLC
| |||
Name of scheme: | The Shield Therapeutics plc 2016 Long Term Incentive Plan | |||
Period of return: | From: | 01 October 2020 | To: | 31 March 2021 |
Balance of unallotted securities under scheme(s) from previous return: | 171,883 | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | NIL | |||
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | -147,610 | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 24,273 | |||
Name of applicant: | SHIELD THERAPEUTICS PLC | |||
Name of scheme: | Shield Therapeutics Retention and Performance Share Plan | |||
Period of return: | From: | 01 October 2020 | To: | 31 March 2021 |
Balance of unallotted securities under scheme(s) from previous return: | 1,885,819 | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 2,500,000* | |||
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | -1,207,543 | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 3,178,276 | |||
*Please note this number is further to the block listing applied for on the 24th March 2021 and admitted on 30th March 2021. This block listing has been allocated to the Shield Therapeutics Retention and Performance Share Plan in entirety.
Name of contact: | Lucy Huntington-Bailey |
Telephone number of contact: | +44 (0) 191 511 8500 |
For further information, please contact:
Shield Therapeutics plc | +44 (0) 191 511 8500 | ||
Tim Watts (CEO) Lucy Huntington-Bailey, (Company Secretary and General Counsel) |
| ||
|
| ||
Peel Hunt LLP - Nominated Adviser & Joint Broker | +44 (0) 20 7148 8900 | ||
James Steel / Christopher Golden |
| ||
|
| ||
finnCap Ltd - Joint Broker | +44 (0) 20 7220 0500 | ||
Geoff Nash / Alice Lane / Matthew Radley |
| ||
|
| ||
Walbrook PR - Financial PR & IR Adviser | +44 (0) 20 7933 8780 | ||
Paul McManus / Lianne Cawthorne | or shield@walbrookpr.com | ||
About Shield
Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.
Shield's lead product, Feraccru®/Accrufer®, has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. The Group plans to launch Accrufer® in the US during 2021 through a highly experienced sales and marketing team. Feraccru® is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan.
For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx